Kairos Pharma (KAPA) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharmaceutical company focused on immunotherapy and cell therapy for oncology, with no approved products or product revenue as of June 30, 2026.

• Net loss of $3,042 thousand for the six months ended June 30, 2026, compared to $2,684 thousand for the same period in 2025.

• Accumulated deficit reached $17,304 thousand as of June 30, 2026.

• Raised $392 thousand gross ($374 thousand net) through an At the Market (ATM) equity offering in the first half of 2026; $911 thousand raised subsequent to quarter-end.

Financial highlights

• No revenue generated in the six months ended June 30, 2026 or 2025.

• Operating expenses for the six months ended June 30, 2026 were $3,107 thousand, up from $2,722 thousand year-over-year.

• Research and development expenses increased to $1,303 thousand from $989 thousand year-over-year, mainly due to Phase 2 prostate cancer trial.

• General and administrative expenses were $1,804 thousand, up from $1,733 thousand year-over-year.

• Cash and cash equivalents totaled $2,626 thousand as of June 30, 2026, down from $4,491 thousand at December 31, 2025.

Outlook and guidance

• Management expects continued significant operating losses as clinical and preclinical programs advance.

• Existing cash balance may not be sufficient to fund planned operations for the next 12 months; additional funding will be required.

• Company may seek further equity or debt financing, collaborations, or licensing arrangements.